⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLMD News
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
prnewswire.com
GLMD
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
prnewswire.com
GLMD
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
prnewswire.com
GLMD
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
prnewswire.com
GLMD
Galmed Issues CEO Letter to Shareholders
prnewswire.com
GLMD
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
prnewswire.com
GLMD
Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
prnewswire.com
GLMD
Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
prnewswire.com
GLMD
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
prnewswire.com
GLMD